{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["56"],"submitter":["Ramchandren R"],"funding":["Pharmacyclics"],"pubmed_abstract":["<h4>Background</h4>This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR<sup>2</sup> regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem cell transplantation.<h4>Methods</h4>In phase 2, patients with relapsed/refractory non-germinal centre B-cell-like DLBCL received oral ibrutinib 560 mg once daily and oral lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity and intravenous rituximab 375 mg/m<sup>2</sup> on Day 1 of Cycles 1-6. The primary endpoint was overall response rate (ORR) in the response-evaluable population (received any study treatment and had ≥1 post-baseline disease assessment). Th"],"journal":["EClinicalMedicine"],"pagination":["101779"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9813677"],"repository":["biostudies-literature"],"pubmed_title":["The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study."],"pmcid":["PMC9813677"],"pubmed_authors":["Kassam S","Ping J","Cunningham D","Szafer-Glusman E","Johnson P","Morgan D","Johnson R","Ramchandren R","Goy A","Verhoef G","Eckert K","Ruan J","Munoz J","Ghosh N","Radford J","Offner F","de Vos S","Bailly S","Fayad L","Neuenburg JK","Ardeshna KM"],"additional_accession":[]},"is_claimable":false,"name":"The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.","description":"<h4>Background</h4>This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR<sup>2</sup> regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem cell transplantation.<h4>Methods</h4>In phase 2, patients with relapsed/refractory non-germinal centre B-cell-like DLBCL received oral ibrutinib 560 mg once daily and oral lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity and intravenous rituximab 375 mg/m<sup>2</sup> on Day 1 of Cycles 1-6. The primary endpoint was overall response rate (ORR) in the response-evaluable population (received any study treatment and had ≥1 post-baseline disease assessment). Th","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-07-14T21:08:42.139Z","creation":"2025-04-06T00:51:15.391Z"},"accession":"S-EPMC9813677","cross_references":{"pubmed":["36618900"],"doi":["10.1016/j.eclinm.2022.101779"]}}